Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant

Kuypers, Julia; Simmance, Natalie; Quach, Hang; Hastie, Katherine; Kiss, Nicole

doi:10.1007/s00520-022-07358-y

Cited by 6 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 58 , 59 However, study demonstrated that nutrition support was not associated with neutrophil engraftment time. 59 As above, nutritional status could have potential association with neutrophil and platelet engraftment. Further investigation was warranted to understand the interplay which could contribute to refining patient care strategies.…”

Section: Discussionmentioning

confidence: 99%

“…One study showed that high-risk malnutrition patients experienced a longer time for platelet engraftment but not time for neutrophil engraftment. 57 Additionally, researchers pointed out that albumin was associated with time to platelet engraftment, days of total parenteral nutrition (TPN) correlated with time to neutrophil engraftment 58 58,59 However, study demonstrated that nutrition support was not associated with neutrophil engraftment time. 59 As above, nutritional status could have potential association with neutrophil and platelet engraftment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nutritional and Body Composition Changes in Paediatric β-Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study Using Bioelectrical Impedance Analysis

Zhang,

Wang,

Long

et al. 2024

JMDH

View full text Add to dashboard Cite

Objective This retrospective study evaluated nutritional status and body composition changes in paediatric β-thalassemia (β-TM) patients before and after hematopoietic stem cell transplantation (HSCT), using bioelectrical impedance analysis (BIA), and explored their relationship with HSCT outcomes. Methods A cohort of 40 paediatric β-TM patients undergoing allogeneic HSCT was assessed for their nutritional status, anthropometric parameters, including body mass index (BMI), weight, and height, and body composition parameters pre-and post-HSCT, focusing on BIA measurements, including intracellular water (ICW), extracellular water (ECW), fat mass (FAT), fat-free mass (FFM), Skeletal Muscle Mass (SMM), soft Lean Mass (SLM), percent body fat (PBF), Body Cell Mass (BCM), Phase angle (PA) and muscle balance pre- and post-HSCT. Post-HSCT clinical outcomes, including acute graft-vs-host disease (aGVHD), engraftment time, oral mucositis (OM), sinusoidal obstruction syndrome (SOS), and diarrhoea in relation to nutrition status after HSCT were analysed. Results After HSCT, 28.21% experienced diminished nutritional status, with 71.43% of those who were wasting before HSCT showing diminished nutritional status, significantly higher than the normal group (18.75%, P = 0.012). Anthropometric changes included significant weight reduction (87.5%, 22.15 ± 7.46 vs 20.74 ± 6.57, P < 0.001) and BMI decrease (90%, 15.19 ± 1.70 vs 14.05 ± 1.48, P < 0.001). Body composition parameters, which are FFM, SMM, SLM, ICW, ECW, BCM, and PA (18.26 ± 5.71 vs 17.27 ± 5.19, 8.68 ± 3.30 vs 7.93 ± 3.02, 17.11 ± 5.28 vs 16.06 ± 4.84, 8.19 ± 2.54 vs 7.62 ± 2.31, 5.15 ± 1.58 vs 4.94 ± 1.47, 11.74 ± 3.63 vs 10.92 ± 3.32, 4.42 ± 0.50 vs 3.90 ± 0.57, respectively, P < 0.001) analysis revealed significant decreases. No significant differences in clinical outcomes were observed based on nutritional status. Conclusion Paediatric β-TM patients undergoing HSCT exhibit significant changes in nutrition status and body composition, emphasizing the need for focused attention on malnourished children who are more prone to diminished nutritional status. Comprehensive BIA aids in understanding the impact, urging consideration for extended follow-up and larger cohorts in future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Nutritional and Body Composition Changes in Paediatric β-Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study Using Bioelectrical Impedance Analysis

Zhang,

Wang,

Long

et al. 2024

JMDH

View full text Add to dashboard Cite

show abstract

“…Bortezomib combined with dexamethasone and lenalidomide can produce regulation of immune cell subpopulations, affect the activity of proteases, intervene in the cell cycle and apoptosis regulatory proteins, mediate the immune response to regulate the number and function of immune cells, inhibit the antigenic expression of macrophages and dendritic cells, inhibit the proliferation of the cells, prompt the activation of autophagy, enhance the activity of T-cells and their proliferation, and regulate macrophage activity that enhances the interaction between immune cells and immune response [10] . Therefore, bortezomib combined with dexamethasone and lenalidomide regulates immune cells CD3+, CD4+, and CD8+, regulates the function of the immune system, and enhances the immune surveillance and killing effect of the tumor microenvironment, and achieves good therapeutic effects [11] .…”

Section: Discussionmentioning

confidence: 99%

Treatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma

Yuan,

Cui,

Liu

2024

JCNR

View full text Add to dashboard Cite

Objective: To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma. Methods: 60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly, with 30 cases in each group. Bortezomib combined with dexamethasone was administered in the control group, and bortezomib combined with dexamethasone and lenalidomide was given to the observation group, and the treatment effect was analyzed. Results: After treatment, CD3+ and CD4+ of the observation group were higher than that of the control group, CD8+ was lower than that of the control group, and the total treatment efficiency was higher, which was statistically significant (P < 0.05), and there was no difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe, thus it can be promoted in clinical practice.

show abstract

“…The risk factors of malnutrition/cachexia in cancer patients include more advanced disease stage, some tumor locations, more aggressive type of treatment, comorbidities, and low initial body weight [11]. Additionally, after aHSCT, patients are at risk of malnutrition due to CTH-related toxicity, higher risk of infection, and longer hospital stays [12]. Based on the guidelines proposed by the European Society of Clinical Nutrition and Metabolism (ESPEN), malnutrition was divided into three categories: disease-related malnutrition (DRM) with inflammation, DRM without inflammation, and malnutrition without comorbid disease [13].…”

Section: Introductionmentioning

confidence: 99%

IL1B Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients

Mazurek,

Szudy-Szczyrek,

Homa-Mlak

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial infections, and renal damage. Nutritional disorders, especially malnutrition, are noted in about 35–71% of MM patients. Interleukin 1 beta (IL-1β) is a proinflammatory cytokine responsible for muscle atrophy and lipolysis during malnutrition and cachexia. This study aimed to evaluate the usefulness of the IL1B single-nucleotide polymorphism (SNP) (rs1143634) and plasma concentration of IL-1β in the assessment of the risk of nutritional disorders and prognosis in patients with MM. Methods: In our study, 93 patients with the de novo MM were enrolled. The real-time PCR with specific TaqMan probes method was used in genotyping. The IL-1β ELISA kit was used to determine IL-1β concentration in plasma samples. Results: Patients with the CC genotype, compared to the carriers of the other variants of the IL1B, demonstrated significantly higher concentrations of IL-1β in plasma (7.56 vs. 4.97 pg/mL), a significantly higher risk of cachexia (OR = 5.11), and a significantly higher risk of death (HR = 2.03). Moreover, high IL-1β plasma level was related to a significantly higher risk of cachexia (OR = 7.76); however, it was not significantly associated with progression-free survival (PFS) or overall survival (OS). Conclusions: Determination of the IL1B SNP (rs1143634) and plasma concentration of IL-1β may be useful in the assessment of the risk of cachexia and prognosis in patients with MM.

show abstract

Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant

Cited by 6 publications

References 51 publications

Nutritional and Body Composition Changes in Paediatric β-Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study Using Bioelectrical Impedance Analysis

Nutritional and Body Composition Changes in Paediatric β-Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study Using Bioelectrical Impedance Analysis

Treatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma

IL1B Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients

Contact Info

Product

Resources

About